Efruxifermin (FGF-21 mimetic)

2026-06-03 — Novo Nordisk lists several recent corporate updates: it announces the launch of a Wegovy® pill in the United Arab Emirates as part of efforts to expand global access to obesity care. The company also highlights an upcoming cardiometabolic R&D update at the American Diabetes Association’s 2026 Scientific Sessions (dated 2026-05-27) featuring new data for CagriSema and zenagamtide, and references a global observational study (dated 2026-05-26) reporting that “2 in 5” people with cardiovascular disease have cardiovascular inflammation, which is associated with increased risk of heart attack and stroke. Business/clinical significance in the provided text centers on geographic expansion for an obesity treatment and continued pipeline/data generation in cardiometabolic disease, but no trial design details, numerical outcomes beyond “2 in 5,” or regulatory/commercial terms are included.